TrialHaematologica2024

Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.

Matthew J Maurer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.